Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
FibroGen: Q3 Earnings Snapshot AP - Tue Nov 12, 4:06PM CST

FibroGen: Q3 Earnings Snapshot

FGEN : 0.3601 (+2.89%)
FibroGen Reports Third Quarter 2024 Financial Results GlobeNewswire - Tue Nov 12, 3:05PM CST

FGEN : 0.3601 (+2.89%)
FibroGen to Report Third Quarter 2024 Financial Results GlobeNewswire - Mon Nov 4, 3:05PM CST

FGEN : 0.3601 (+2.89%)
FibroGen: Q2 Earnings Snapshot AP - Tue Aug 6, 4:10PM CDT

FibroGen: Q2 Earnings Snapshot

FGEN : 0.3601 (+2.89%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments Newswire.ca - Wed Jun 12, 9:22AM CDT

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 35.5000 (+1.05%)
ONCY : 0.9887 (-0.98%)
VSTM : 4.05 (+6.86%)
CADL : 4.16 (+4.52%)
FGEN : 0.3601 (+2.89%)
REGN : 748.23 (+0.66%)
ONC.TO : 1.38 (-1.43%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases BayStreet.ca - Wed Jun 12, 9:11AM CDT

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.9887 (-0.98%)
ONC.TO : 1.38 (-1.43%)
RHHBY : 35.5000 (+1.05%)
VSTM : 4.05 (+6.86%)
CADL : 4.16 (+4.52%)
FGEN : 0.3601 (+2.89%)
REGN : 748.23 (+0.66%)
Wall Street - shutterstock_94127350
Stock Index Futures Slip on Growth Fears, U.S. JOLTs Report in Focus Barchart - Tue Jun 4, 4:39AM CDT

June S&P 500 E-Mini futures (ESM24) are down -0.36%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.34% this morning after weak manufacturing data raised concerns about the U.S. economic health,...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
PARA : 10.97 (+3.69%)
NVDA : 145.97 (+0.05%)
BA : 143.44 (-1.81%)
SAIC : 125.15 (+1.71%)
FANG : 182.87 (+0.78%)
DVN : 38.76 (+1.20%)
CRWD : 358.46 (+2.37%)
FERG : 206.33 (+1.77%)
PVH : 98.66 (+2.27%)
HPE : 21.85 (+3.16%)
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032 BayStreet.ca - Mon Jun 3, 8:33AM CDT

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 0.9887 (-0.98%)
ONC.TO : 1.38 (-1.43%)
VSTM : 4.05 (+6.86%)
CTMX : 0.8719 (+0.21%)
BNTX : 106.56 (+4.33%)
FGEN : 0.3601 (+2.89%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Newswire.ca - Mon Jun 3, 8:17AM CDT

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 0.9887 (-0.98%)
VSTM : 4.05 (+6.86%)
CTMX : 0.8719 (+0.21%)
BNTX : 106.56 (+4.33%)
FGEN : 0.3601 (+2.89%)
ONC.TO : 1.38 (-1.43%)
FibroGen: Q1 Earnings Snapshot AP - Mon May 6, 3:25PM CDT

FibroGen: Q1 Earnings Snapshot

FGEN : 0.3601 (+2.89%)

Barchart Exclusives

ELF’s Unusual Options Activity Is a Thing of Questionable Beauty Barchart - 47 minutes ago
E.L.F. Beauty’s options volume on Wednesday was 7x the 30-day average. The affordable makeup and skincare company’s unusual options activity stood out as one investor questioned its revenues. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot